Theravance Biopharma (NASDAQ:TBPH) Issues Earnings Results

Theravance Biopharma (NASDAQ:TBPH) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. The business had revenue of $16.87 million for the quarter, compared to analyst estimates of $16.11 million. Theravance Biopharma had a negative return on equity of 24.23% and a negative net margin of 78.18%. During the same quarter in the previous year, the firm posted ($0.17) EPS.

Theravance Biopharma Trading Up 8.6 %

Shares of NASDAQ TBPH opened at $9.68 on Thursday. The stock has a market cap of $473.56 million, a price-to-earnings ratio of -9.58 and a beta of 0.25. The company’s 50-day moving average price is $8.32 and its 200 day moving average price is $8.68. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.71.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TBPH shares. TD Cowen decreased their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of “Hold” and an average price target of $13.75.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at $2,904,687. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.90% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.